Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2233462/sarepta-therapeutics-srpt-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233462
Feb 28, 2024 - The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
https://www.zacks.com/stock/news/2229472/sarepta-srpt-to-report-q4-earnings-will-it-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2229472
Feb 21, 2024 - Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
0
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
https://www.zacks.com/stock/news/2228601/sarepta-therapeutics-srpt-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228601
Feb 20, 2024 - Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
https://www.zacks.com/stock/news/2227756/can-rigel-pharmaceuticals-rigl-beat-q4-earnings-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227756
Feb 19, 2024 - Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.
0
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548
Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
0
Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?
https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400
Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.
0
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
https://www.zacks.com/stock/news/2224881/what-s-in-the-cards-for-medtronic-mdt-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2224881
Feb 12, 2024 - Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
0
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
https://www.zacks.com/stock/news/2222832/exelixis-exel-q4-earnings-beat-on-lower-r-d-spend-sales-miss?cid=CS-ZC-FT-analyst_blog|earnings_article-2222832
Feb 07, 2024 - Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
0
IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?
https://www.zacks.com/stock/news/2217329/idexx-laboratories-idxx-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217329
Jan 29, 2024 - Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.
0
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213712
Jan 22, 2024 - Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
0